Multicentre tumour marker reference range study.
Anticancer Res
; 19(4A): 2749-52, 1999.
Article
em En
| MEDLINE
| ID: mdl-10470234
ABSTRACT
BACKGROUND:
The array of antibodies and assay formats utilised by kit manufacturers contribute to different values being quoted as clinically "normal". Kit-specific reference range limits will maximise the clinical utility of tumour marker assays. MATERIALS ANDMETHODS:
Serum samples (approximately 800) were obtained from volunteers, age 20-70 years, in France, Germany, The Netherlands and Portugal. Each sample was assayed with a number of DPC tumour markers kits. IMMULITE assays were carried out in The Netherlands; Coat-A-Count IRMA, IRMA-Count, Double Antibody and Milenia assays at EURO/DPC Ltd. Analytes included, BR-MA, OM-MA, GI-MA (for the determination of CA 15-3, CA 125 and CA 19-9, respectively), CEA, PSA, PAP and HCG.RESULTS:
The median and 95th percentiles for each analyte in each assay format were estimated; where appropriate, data subsets were considered.CONCLUSION:
Kit-specific reference range data generated for important tumour marker analytes will help clinicians interprete their assay results.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Reino Unido